Anti-Diabetes Drugs - Sweden

Sweden

In Sweden, the revenue in the Anti-Diabetes Drugs market is expected to reach US$263.90m in 2024.
Looking ahead, the revenue is projected to experience a steady annual growth rate (CAGR 2024-2028) of 5.20%, ultimately leading to a market volume of US$323.20m by 2028.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$35,630.00m in 2024.
Sweden's government-funded healthcare system has driven the demand for innovative anti-diabetes drugs in the country.

Key regions: India, Canada, Australia, France, Italy

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Diabetes Drugs in Sweden has been on the rise in recent years.

Customer preferences: The increasing prevalence of diabetes in Sweden has led to a growing demand for Anti-Diabetes Drugs. Many Swedish patients prefer oral medications over insulin injections, which has driven the growth of the oral anti-diabetic drugs market. Additionally, there is a growing preference for combination drugs that offer a more convenient treatment option.

Trends in the market: The Anti-Diabetes Drugs market in Sweden is expected to continue to grow in the coming years, driven by factors such as an aging population and a growing prevalence of obesity. The market is also expected to see an increase in the use of newer, more expensive drugs as patients seek more effective treatments.

Local special circumstances: Sweden has a well-established healthcare system that provides free access to healthcare for all residents. This has led to a high level of healthcare utilization, including for the treatment of diabetes. Additionally, the Swedish government has implemented policies aimed at reducing the prevalence of diabetes, including public health campaigns and efforts to promote healthy lifestyles.

Underlying macroeconomic factors: Sweden has a strong economy and a high standard of living, which has allowed for increased healthcare spending. Additionally, the country has a well-educated population that is knowledgeable about healthcare and health-related issues. These factors have contributed to a high level of demand for Anti-Diabetes Drugs in Sweden.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.